Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vanguard U.S. Momentum Factor ETF (NY:VFMO)

194.93 -2.30 (-1.17%)
Official Closing Price Updated: 8:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Vanguard U.S. Momentum Factor ETF

< Previous 1 2 Next >
Fiserv Shares Plunge 44% In Record One-Day Drop As Company Gets Wall Street Downgrades On Leadership Changes, Forecast Cuts
Wolfe Research downgraded Fiserv to ‘Peer Perform’ from ‘Outperform,’ according to TheFly, on the heels of the guidance cut that it says "raised structural concerns." 
Via Stocktwits
BridgeBio Shares Second Positive Late-Stage Study Result In A Week – Calcium Disorder Drug Trial Yields Positive Results
76% of the 67 participants administered Encaleret in the trial achieved both serum and urine calcium within the respective target ranges after 24 weeks of treatment. 
Via Stocktwits
Fiserv Stock Plunges 32% As New CFO Paul Todd Steps In Amid Leadership Overhaul, Profit Warning
Fiserv now expects 2025 adjusted earnings per share to come between $8.50 and $8.60, down from the previous forecast of $10.15 to $10.30. 
Via Stocktwits
Tango Therapeutics Stock Soars Pre-Market On $225M Financing, Positive Study Data For Cancer Therapy
CEO Barbara Weber said that across the 16 cancer types enrolled in the trial, the objective response rate (ORR) was 27% in patients with a median follow-up of 9.4 months. 
Via Stocktwits
Carvana Stock In Spotlight After 6% Slide Today: BTIG Maintains ‘Buy’ Rating
Via Stocktwits
Jefferies CEO Claims Bank Was ‘Defrauded’ By Bankrupt Auto Supplier First Brands Group
Via Stocktwits
Topics Bankruptcy Supply Chain
Jeff Bezos Reportedly Says People Should Be Thrilled About AI: ‘Don’t See How Anybody Can Be Discouraged Who Is Alive’
Via Stocktwits
Arcturus Therapeutics Stock Plunges Over 57% Today: What’s Causing The Sell-Off?
The company said that treatment-related adverse events were observed in the study for the first few doses but ceased with continuous dosing. 
Via Stocktwits
Eli Lilly Says Verzenio Reduced Risk of Death In Late-Stage Trial In Some Breast Cancer Patients
Via Stocktwits
Boston Scientific To Acquire Privately-Held Pain Solutions Developer Nalu Medical For About $533M
Via Stocktwits
Sana Biotech Stock Jumps A Whopping 35% After Eric Jackson Calls It ‘Next 100-Bagger Platform’
Via Stocktwits
FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older. 
Via Stocktwits
Apollo Global Eyes Spanish Market With Focus On Energy, Data Centers, And Infrastructure: Report
According to a Bloomberg News report, these sectors are where Apollo will be looking for players with the “biggest needs.” 
Via Stocktwits
Topics Government
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level
Via Stocktwits
Eli Lilly Terminates Study Of Bimagrumab In Obesity
Via Stocktwits
Eli Lilly Announces Plan To Construct New $6.5B Facility In Texas
Via Stocktwits
Scholar Rock In Spotlight After FDA Refuses To Approve Muscular Atrophy Treatment Over Third-Party Manufacturing Facility Issues
Via Stocktwits
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year
Via Stocktwits
Uber Inks Partnership With Flytrex For Drone Delivery In US: Retail Sees Stock ‘Going Higher For Longer’
Via Stocktwits
Roivant Stock Rises After Drug Achieves Goals In Late-Stage Study: Retail Sees Further Rally To $17
Once-daily oral Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and all key secondary endpoints in the study,... 
Via Stocktwits
Duolingo Stock Dips After Citigroup Lowers Price Target – Here’s What The Analyst Said About Duocon Event
Citigroup maintained a ‘Buy’ rating and noted that Duolingo's product announcements this year had a lower profile relative to the past. 
Via Stocktwits
Topics Artificial Intelligence
Eli Lilly To Set Up $5B Facility In Virginia – More Details Inside
Via Stocktwits
Ralph Lauren Unveils Three-Year Outlook – Here Are The Key Points
Via Stocktwits
Caleres Draws ‘Less Risk’ Rating From Telsey, Retail Chatter Surges 700%
Via Stocktwits
Iovance Stock Rises 4% On Health Canada Approval For Cancer Immunotherapy: Retail Thinks ‘Patience Will Pay Off’
Via Stocktwits
Dave & Buster’s Sees Wall Street Downgrades, Yet Retail Sentiment Red-Hot
UBS said that while Dave & Buster’s was still in the early stages of a turnaround, with macro pressure remaining elevated and visibility limited, an eventual return to consistently positive same-store... 
Via Stocktwits
Summit Therapeutics Gets A $40 Price Target As Guggenheim Says It Likes Stock At $24, Like It Did At $3
The price target of $40 represents an upside of 70% from the stock’s closing price on Wednesday. 
Via Stocktwits
Agios Pharma Stock Slumped 15% Today But Company Remains Top Pick For This Analyst – Find Out More
While the FDA was originally expected to decide on the company’s application for Pyrukynd in treating thalassemia by September 7, its decision is now expected by December 7. 
Via Stocktwits
Zymeworks Stock Tanks Over 17% After Cancer Drug Candidate Update
The company was testing the drug in an early-stage trial in patients with ovarian cancer and non-small cell lung cancer. 
Via Stocktwits
Lyft Has A ‘Steady Path Forward’ According To UBS: Retail Thinks Stock Is Undervalued
Via Stocktwits
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.